At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Stock Information for Immix Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immix Biopharma Inc.

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.